Ivagalmin 1,5 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ivagalmin 1,5 mg trde kapsule

genepharm (europe) trading ltd. - rivastigmin - kapsula, trda - rivastigmin 1,5 mg / 1 kapsula - rivastigmin

Ivagalmin 3 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ivagalmin 3 mg trde kapsule

genepharm (europe) trading ltd. - rivastigmin - kapsula, trda - rivastigmin 3 mg / 1 kapsula - rivastigmin

Ivagalmin 6 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ivagalmin 6 mg trde kapsule

genepharm (europe) trading ltd. - rivastigmin - kapsula, trda - rivastigmin 6 mg / 1 kapsula - rivastigmin

Ivagalmin 4,5 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ivagalmin 4,5 mg trde kapsule

genepharm (europe) trading ltd. - rivastigmin - kapsula, trda - rivastigmin 4,5 mg / 1 kapsula - rivastigmin

Comirnaty Evropska unija - slovenščina - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

OMNIPAQUE 240 mg I/ml raztopina za injiciranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

omnipaque 240 mg i/ml raztopina za injiciranje

ge healthcare as - jod - raztopina za injiciranje - jod 240 mg / 1 mljoheksol - joheksol

OMNIPAQUE 300 mg I/ml raztopina za injiciranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

omnipaque 300 mg i/ml raztopina za injiciranje

ge healthcare as - jod - raztopina za injiciranje - jod 300 mg / 1 ml - joheksol

OMNIPAQUE 350 mg I/ml raztopina za injiciranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

omnipaque 350 mg i/ml raztopina za injiciranje

ge healthcare as - jod - raztopina za injiciranje - jod 350 mg / 1 mljoheksol - joheksol

OMNIPAQUE 350 mg I/ml raztopina za injiciranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

omnipaque 350 mg i/ml raztopina za injiciranje

ge healthcare as - jod - raztopina za injiciranje - jod 350 mg / 1 ml - joheksol

OMNIPAQUE 350 mg I/ml raztopina za injiciranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

omnipaque 350 mg i/ml raztopina za injiciranje

ge healthcare as - jod - raztopina za injiciranje - jod 350 mg / 1 mljoheksol - joheksol